Figure 3
From: Identification of PADI2 as a potential breast cancer biomarker and therapeutic target
RNA-seq analysis of PADI2 expression across 57 breast cancer cell lines shows subtype specific expression and high correlation with HER2/ERBB2 . The Spearman correlation between PADI2 and HER2/ERBB2 overexpression was highly significant across the luminal, basal-NM, and claudin-low cell lines (rho = 0.828, p = 2.2 × 10-16). A significant anti-correlation between PADI2 and HER2/ERBB2 was observed across the basal cell lines (rho = −0.495, p = 0.045).